This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 3.33% and 1.15%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
by Zacks Equity Research
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Best Momentum Stocks to Buy for January 25th
by Zacks Equity Research
ETON, OKTA and VZLA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 25, 2023.
New Strong Buy Stocks for January 25th
by Zacks Equity Research
YEXT, CXM, ETON, OKTA, VZLA have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
by Zacks Equity Research
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
by Zacks Equity Research
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
Best Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
ETON, KMTUY and AU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 23, 2023.
New Strong Buy Stocks for January 23rd
by Zacks Equity Research
GFI, AU, ETON, KMTUY and STLA have been added to the Zacks Rank #1 (Strong Buy) List on January 23, 2023.
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
by Zacks Equity Research
Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
by Zacks Equity Research
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation
by Zacks Equity Research
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
by Zacks Equity Research
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
by Zacks Equity Research
Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 20% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?